Publication Name	World Journal of Diabetes
Manuscript ID	9213
Country	Ireland

Received	2014-01-27 11:07
Peer-Review Started	2014-01-27 21:51
To Make the First Decision	2014-02-27 09:35
Return for Revision	2014-03-11 21:10
Revised	2014-07-23 00:00
Second Decision	2014-07-29 08:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-07-29 09:06
Articles in Press	2014-07-29 09:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-05 18:42
Publish the Manuscript Online	2014-08-17 13:16

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Nutrition & Dietetics
Manuscript Type	Review
Article Title	Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Manuscript Source	Invited Manuscript
All Author List	Gerald H Tomkin
Funding Agency and Grant Number
Corresponding Author	Gerald H Tomkin, Professor, Diabetes Institute of Ireland, Beacon Hospital, Sandyford, Clontra, Quinns Road, Shankill, Dublin 18, Ireland. gerald.tomkin@tcd.ie
Key Words	Type 2 diabetes; Lifestyle modification; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 agonists; Insulin
Core Tip	Treatment of diabetes is difficult. Initial success in achieving treatment goals is followed by deterioration and the necessity for additional treatments. Exciting new drugs with new modes of action, have stimulated diabetologists to strive for improved control in the knowledge that complications will be reduced or prevented. Obese patients, who loose weight on glucagon-like peptide-1 agonists are usually delighted with these drugs but for those who fail to loose weight changing to oral dipeptidyl peptidase-4 inhibitors would seem a good choice. sodium-glucose transporter-2 inhibitors have the added benefit of being effective even if blood sugar is near to target but uro-genital infection is a concern.
Publish Date	2014-08-17 13:16
Citation	Tomkin GH. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J Diabetes 2014; 5(5): 636-650
URL	http://www.wjgnet.com/1948-9358/full/v5/i5/636.htm
DOI	http://dx.doi.org/10.4239/wjd.v5.i5.636

Full Article (PDF)	WJD-5-636.pdf
Full Article (Word)	WJD-5-636.doc
Manuscript File	9213-Review.doc
Answering Reviewers	9213-Answering reviewers.PDF
Copyright License Agreement	9213-Copyright assignment.PDF
Peer-review Report	9213-Peer review(s).pdf
Scientific Misconduct Check	9213-CorssCheck.jpg
Scientific Editor Work List	9213-Scientific editor work list.pdf